BeiGene
ONC
#686
Rank
C$40.31 B
Marketcap
$339.67
Share price
-4.40%
Change (1 day)
58.62%
Change (1 year)
BeiGene is a Chinese pharmaceutical company engaged in the R&D, and commercialization of molecularly-targeted, and immuno-oncology drugs for the treatment of cancer.

Earnings for BeiGene (ONC)

Earnings in 2024 (TTM): -C$0.78 Billion

According to BeiGene 's latest financial reports the company's current earnings are C$3.81 Billion. , an increase over its 2023 earnings that were of -C$1.68 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for BeiGene from 2015 to 2024

Annual earnings

Year Earnings Change
2024 -C$0.79 Billion-52.95%
2023 -C$1.68 Billion-32.52%
2022 -C$2.49 Billion24.39%
2021 -C$2 Billion-13.21%
2020 -C$2.3 Billion72.69%
2019 -C$1.34 Billion36.01%
2018 -C$0.98 Billion616.83%
2017 -C$0.14 Billion-15.24%
2016 -C$0.17 Billion107.91%
2015 -C$77.5 Million

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
-C$25.19 Million-96.80%๐Ÿ‡บ๐Ÿ‡ธ USA
-C$14.38 Million-98.18%๐Ÿ‡บ๐Ÿ‡ธ USA